Financials Net sales amounted SEK 211k (SEK 298k in Q1’22). Cash from operating activities came in at SEK -15.5m (SEK -9.6m in Q1’22), increase partly explained by costs associated to moving to the new premises and the patent litigation in the US. Cash and cash equivalents amounted SEK 66.9m (SEK 87.7m in Q1’22).
Implications for the share With no material updates in the report, we expect a neutral share price reaction today. Upcoming milestones include the initiation of the NEX-20 Ph 1 in MM and the announcement of the chosen compound and indication for the NEX-21/22. Nanexa will host a webcast today at 10:00 CET viewable at https://www.youtube.com/watch?v=T76wpbdAq8k.
Läs mer på ABG Sundal Collier
Aktuellt
SENASTE
